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Abstract
Purpose It has been reported that even one year after total
knee arthroplasty (TKA), a relevant percentage of patients
does not attain complete recovery and indicate unfavourable
long-term pain outcome.We compared the clinical outcome of
33 patients undergoing TKA randomly assigned to the control
or the pulsed electromagnetic field group (I-ONE therapy).
Methods I-ONE therapy was administered postoperatively
four hours per day for 60 days. Patients were assessed before
surgery and then at one, two and six months postoperatively
using international scores.
Results One month after TKA, pain, knee swelling and func-
tional score were significantly better in the treated compared
with the control group. Pain was still significantly lower in the
treated group at the six month follow-up. Three years after
surgery, severe pain and occasional walking limitations were
reported in a significantly lower number of patients in the
treated group.
Conclusions Advantages deriving from early control of joint
inflammation may explain the maintenance of results at
follow-up. I-ONE therapy should be considered an effective
completion of the TKA procedure.
Keywords Pulsed electromagnetic fields . Total knee
replacement . Pain . Inflammation . Long-term result
Introduction
In recent decades innovations in total knee arthroplasty (TKA)
biomaterials, design and surgical techniques have increased the
rate of patient satisfaction. However, 11–25 % of patients
report a noticeable improvement with respect to preoperatively
but are still not satisfied with their TKA [1, 2]. It has been
reported that even one year after surgery, a relevant percentage
of patients (37 %) have not attained complete recovery [3] and
indicates unfavourable long-term pain outcome (10 %–34 %)
[4]. It has been suggested that early pain control and joint
inflammation resolution following TKA may prevent long-
term pain and functional limitations in uncomplicated TKAs
[5]. Indeed, the strong local inflammatory component, which is
present for some weeks after TKA surgery, may affect soft-
tissue healing, leading to excess fibrous tissue, hypertrophic
synovitis and heterotopic ossification that sustains chronic
inflammation of the joint [6]. Pro-inflammatory mediators are
directly responsible for several clinical symptoms that reflect
the structural progression of osteoarthritis [7]. In particular, a
significant correlation between interleukin-6 (IL-6) concentra-
tions in joint fluid and functional scores was found one month
after TKA, demonstrating that an intense inflammatory re-
sponse is associated with a slow recovery [8]. It has also been
demonstrated that high pre-operative synovial fluid concentra-
tions of tumor necrosis factor-α (TNF-α), metalloproteinase-
13 (MMP-13) and IL-6 in the knee are predictive of delayed
pain resolution two years following TKA [9]. Moreover, a
significant increase of IL-1β levels in the synovial fluid has
been observed following TKA [10]. Therefore, the synovial
membrane appears to be a promising target for novel strategies
to control inflammation, prevent structural joint alterations and
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treat clinical symptoms, such as pain and swelling, after knee
surgery [7]. Varani et al. [11], after having demonstrated the
presence of A2A or A3 adenosine receptors in human-
fibroblast-like synoviocytes, showed that their modulation
could be used to control inflammatory joint diseases [12].
Indeed, pulsed electromagnetic fields (PEMFs) show agonist
activity for A2A and A3 adenosine receptors, indicating that
they can be used to control local inflammation and manage
joint diseases [11, 12]. In human osteoarthritic fibroblasts,
PEMFs increase the activation of these receptors reducing the
synthesis of inflammatory mediators such as prostaglandin E2
(PGE2) and IL-6 and -8 [13].
Two prospective randomised double-blind trials demon-
strated that patients using PEMFs after knee arthroscopy had
a faster functional recovery and resolution of joint inflamma-
tion in comparison with patients in the placebo group [14, 15].
PEMF was also effective when used for two months after
TKA, favoring functional recovery and early pain relief [16].
The primary objective of this randomised controlled trial in
patients undergoing TKA stimulated with PEMF was to evalu-
ate pain relief during follow-up; the secondary aim of the study
was to determine whether PEMF could reduce joint swelling
and accelerate functional recovery. A phone survey was per-
formed to evaluate the number of patients still experiencing pain
and functional limitation three years post-TKA.
Materials and methods
Patient characteristics
Patients with indication for TKA and satisfying the following
inclusion criteria were enrolled: age between 60 and 85 years,
grade 4 osteoarthrosis (Kellgren-Lawrence classification), varus/
valgus malalignment <20° and 15°, respectively, and flexion
deformity <15°. Previous surgery on the same knee, total hip
arthroplasties, rheumatoid arthritis, autoimmune diseases, sys-
temic diseases, tumors, severe malalignment and body mass
index (BMI) > 30 kg/m2 were considered exclusion criteria.
The study was approved by the Institutional Review Board and
registered at Current Controlled Trials (www.controlled-trials.
com; doi:10.1186/ISRCTN98459871). All the patients signed
the informed consent.
Randomisation process and I-ONE therapy protocol
Patients were randomly assigned to the treated or control group
using a web-based randomisation program built on the
randomisation criteria: sex (M/F), age (60–75 years; 75–85 years)
and smoking status (yes/no). Patients allocated to the treated
group by a research assistant not involved in patient assessment
were instructed to use PEMF (I-ONE therapy, IGEA, Carpi,
Italy) for four hours per day for 60 days. Treatment was started
within seven days from surgery. The coils, placed on the operated
knee, were powered by the PEMF generator system, which
produces a pulsed signal with the following parameters: peak
magnetic field intensity 1.5±0.1 mT; frequency 75 Hz
(patented). The patient could wear the battery-operated device
during day or night and was instructed to interrupt treatment in
case of adverse events, such as a burning sensation or skin
irritation. The principal investigator and all physicians in charge
of clinical controls were blinded to patient allocation.
Surgical procedure and rehabilitation program
All patients received a cemented posterostabilised (PS) TKA
(Vanguard®, Biomet,Warsaw, IN, USA)with patella resurfacing
using a tourniquet and a medial parapatellar approach without
patella eversion. All surgeries were performed by the same senior
surgeon and the same anaesthesiologist. Patients were
anaesthetised by selective spinal subarachnoid injection and
positioning of an indwelling catheter at the femoral nerve level.
In all patients, infiltration of the capsule with a periarticular
injection of 120 ml ropivacaine 0.2 % 250 mg and epinephrine
1/1,000 0.5 mg was performed. To improve pain control and
reduce the need for nonsteroidal anti-inflammatory drugs
(NSAIDs) in the immediate postoperative period, elastomeric
endovenous pump with 40–60 ml of ketoprofen and 20–30 ml
of morphine and femoral perineural catheter with 0.3 % naropin
for 48 hours were administered. Both patient groups followed a
standard rehabilitation protocol: active and passive mobilisation
of hip, knee and ankle using Kinetec (Rioveggio, Italy) from day
one after surgery, accordingly to pain tolerance; from day two,
assisted walking with two crutches; progressive weight-bearing
regimen with discontinuation of crutch use according to each
patient.
Radiological assessment
To evaluate knee alignment, before surgery and a few days
postsurgery, coronal-plane alignment was measured from
standard weight-bearing anteroposterior (AP) radiographs
with the knee in full extension [17].
Clinical evaluation
All patients were clinically evaluated before surgery and then
at one, two and six months after TKA. At each control, visual
analogue scale (VAS) for pain, Knee Society Score (KSS)
clinical rating system, the Short Form 36 (SF-36) Health
Survey questionnaire were determined. Moreover, joint swell-
ing was evaluated accordingly to Soderberg [18] using the
following scores: 40, no difference between knee girth; 30,
<0.5 cm; 20, between 0.5 and 1 cm; 10, between 1 and 1.5 cm;
0, >1.5 cm. An average of 3 years of follow-up phone surveys
398 International Orthopaedics (SICOT) (2014) 38:397–403
was performed: KSS function, persistence of pain and use of
NSAIDs were recorded for each patient.
Statistical analysis
Pain (VAS) was considered the primary outcome and used to
calculate sample size of the study. According to the literature
[14–16], a difference in mean VAS of 2 units between the two
groups after the first month of therapy, with a standard devi-
ation (SD) of 2 units, was hypothesised. To reach a statistical
significance of 95 % with a power of 80 %, the sample size of
each study group was equal to 15 subjects. Student’s t test was
used to calculate mean variations for each parameter at each
follow-up, with respect to baseline and to compare groups.
Data are expressed as mean ± SD; p <0.05 was considered
statistically significant.
Results
Fifty-eight consecutive patients with indication for TKAwere
assessed for eligibility, of which only 33 (18 males, 15 fe-
males) matched the inclusion criteria. Data about 26 patients
(12 treated group, 14 control group) were then available for
final analyses (Fig. 1). At the time of enrollment the
background population features were homogeneous between
groups (Table 1).
I-ONE therapy was well tolerated by all patients, with no
side effects.
Coronal alignment
Varus and valgus knees were equally distributed in the two
groups before surgery (not significant). Postoperative coronal
Fig. 1 Consolidated Standards of
Reporting Trials (CONSORT)
flow chart for patient enrolment






Sex 10 F, 6 M 9 F, 8 M n.s.
Age (years) 66±13 73±5 n.s.
Height (cm) 169±5 167±10 n.s.
Weight (kg) 78±11 77±12 n.s.
KSS function score 51±18 48±11 n.s.
KSS knee score 12±12 11±20 n.s.
Knee swelling 24±5 26±6 n.s.
VAS 6.1±2.0 5.8±1.6 n.s.
SF-36 33±12 37±11 n.s.
KSS Knee Society Score, VAS visual analogue scale, SF-36 Short-Form
Health Survey questionnaire, n.s . not significant
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alignment was 3.5° and 2.6° for treated and control group,
respectively (not significant).
VAS pain
Pain reduction was statistically significant for both groups
with respect to preoperative level one month after TKA,
although it was more evident in the treated group (−61 %,
p <0.001 and −26 % p <0.05 for treated and control groups,
respectively). Indeed, a significant difference between groups
was observed at the one month follow-up in favour of the
treated group (p <0.05). Throughout the study, patients in the
treated group showed lower VAS values in comparison with
those in the control group, and at six months this difference
was again significant (p <0.05), with a 90 % pain reduction
from baseline in the treated group. Moreover, it is noteworthy
that the average VAS value of the treated group one month
after surgery was comparable with that registered for the
control group at six months (2.4±2.3 and 1.9±2.0, respective-
ly; not significant) (Fig. 2).
KSS: function and knee score
One month after surgery, the treated group showed a signifi-
cant improvement in comparison with the preoperative value
(+30 %; p <0.05), whereas the control group presented com-
parable values with respect to baseline (+15 %; not signifi-
cant). As a consequence, the difference between groups was
statistically significant, with higher scores in the treated group
(p <0.05). Two and six months after surgery the functional
score of both groups significantly improved with respect to
baseline (p <0.001), with no significant difference between
groups (Fig. 3, left side). Also, the KSS knee score significant-
ly improved in both groups beginning from one month after
TKA (p <0.001), with a constant increase over time but with
no significant difference between groups (Fig. 3, right side).
Swelling
One month after TKA, swelling evaluation showed signifi-
cantly better results in comparison with baseline values in the
treated group (−34 %; p <0.01). On the other hand, patients in
the control group presented comparable values with respect to
baseline. Indeed, significantly better results were observed in
the treated group at the 1- (p <0.01) and two month follow-
up (p <0.05). Knee swelling resolution was observed in both
groups at six months (Fig. 4).
SF-36 Health Survey
One month after surgery, the SF-36 of both groups signifi-
cantly increased in comparison with baseline (+32 % and +
22 % for treated and control groups, respectively; p <0.05).
Patient satisfaction continued to improve until six months
after TKA (+96 % and +88 % for treated and control groups,
respectively; p <0.001), but with no significant difference
between groups (Fig. 5). It is noteworthy that one month after
surgery, the SF-36 pain evaluation showed a significant
Fig. 2 Visual analogue score (VAS) pain evaluation of patients before
and 1, 2 and 6 months after total knee arthroplasty (TKA). **p<0.01;
***p <0.001 for each follow-up vs baseline; $p <0.05 for the pulsed
electromagnetic field (I-ONE) therapy group vs control group
Fig. 3 Knee Society Score
(knee and function scores) of
patients before surgery and at 1, 2
and 6 months after total knee
arthroplasty (TKA). **p <0.01;
***p <0.001 for each follow up
vs baseline. $p <0.05 for the
pulsed electromagnetic field
( I-ONE) therapy group vs
control group
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improvement for the treated group only, thus confirming
results of the VAS evaluation (p <0.05) (data not shown).
Long-term follow-up
Patients with persistent pain represented 7 % of the treated
group and 33% of the control group (p <0.05). All the patients
in the treated group reported walking without limitation or
walking aids, whereas 27 % of patients in the control group
occasionally used walking aids (p <0.05) (Fig. 6).
Discussion
Results of this study show that I-ONE therapy in patients who
underwent TKA and the standard rehabilitation protocol
significantly reduced pain and joint swelling and improved
early functional recovery compared with patients who simply
followed standard rehabilitation procedures. At one month
follow-up, I-ONE therapy was particularly effective on knee
swelling and on function, as standard rehabilitation alone did
not allow significant improvement in these parameters with
respect to pre-operative level. The earlier resolution of knee
swelling observed using I-ONE therapy is remarkable, as it
has been demonstrated to be highly important during the acute
period after TKA to follow an adequate rehabilitation program
[19]. Moreover, an inverse relationship between immediate
functional recovery and inflammatory response after hip and
knee arthroplasty is reported [8, 20]. These observations sup-
port the idea that the positive effect of I-ONE therapy on early
outcome can be explained by a reduction in joint inflamma-
tion, as it has already been demonstrated that I-ONE therapy
acts through the agonist activity for the A2A adenosine recep-
tors, leading to reduced local inflammatory processes [11–13,
21–23]. This is particularly relevant in patients undergoing
TKA, as local joint inflammation originating from the severe
osteoarthritis and from the surgical procedure [9] is often
associated with abundant swelling and pain. Among the non-
operative measures useful to improve functional recovery of
patients undergoing total joint replacement, PEMF treatment
is scarcely investigated [23], and to our knowledge, only two
clinical studies have been published [16, 24].
In our study, functional recovery and pain reduction were
observed in both groups and improved until six months. Nev-
ertheless, within the first two months after TKA, results were
more evident among I-ONE therapy patients, with statistically
significant differences with respect to untreated patients. One
of the most important findings of this study is that control
patients who reported pain two months after TKA also
complained of pain at the three year follow-up. Moreover,
Fig. 5 Short-Form Health Survey of 36 questions (SF-36) evaluation of
patients before and 1, 2 and 6 months after total knee arthroplasty (TKA).
*p <0.05; **p <0.01; ***p<0.001 for each follow-up vs baseline
Fig. 6 Long-term follow-up: percentage of patients still having se-
vere pain (left ) and occasionally requiring walking aids (right ) 3 years
after total knee arthroplasty (TKA). $p <0.05 for the pulsed magnetic
field (I-ONE) therapy group vs control group
Fig. 4 Swelling evaluation of patients before and 1, 2 and 6 months after
total knee arthroplasty (TKA). Swelling, evaluated on palpation by the
physician, is described using a scale ranging from 0 to 40, where higher
scores indicate better results. *p <0.05; **p <0.01; ***p <0.001 for each
follow-up vs baseline. $p<0.05; $$p <0.01 for the pulsed magnetic field
(I-ONE) therapy group vs control group
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patients in the treated group experienced faster resolution of
pain and joint swelling, and only one patient reported pain
requiring the use of NSAIDs at the three year follow-up. These
observations again confirm that the early resolution of local
inflammatory response after TKA is essential to enable patients
to follow an adequate rehabilitation program attain functional
recovery and especially to achieve better the long-term results
[4, 19, 23]. As no signs of instability or incorrect component
positioning were observed in either group after TKA, and no
patient was scheduled for a second surgery on the same knee,
our observations confirm that medium- to long-term results do
not strictly depend on biomechanical outcome only but that
important functional limitations can derive from an excessive
reaction of joint soft tissues, including tissue fibrosis, hetero-
topic ossification and synovial reaction. These complications
can be prevented by I-ONE therapy, which facilitates inflam-
mation resolution and favours joint soft tissues healing by
inhibiting the release of PGE2 and proinflammatory cytokines
IL-6 and IL-8 and by stimulating the release of IL-10.
Interestingly, Feng et al. [25] show that pre-operative ad-
ministration of cyclooxygenase-2 inhibitor can greatly ame-
liorate pain associated with TKA, reducing general and local
inflammatory reactions. In light of this study, we could con-
sider evaluating the efficacy of pre-operative I-ONE therapy
on final TKA outcome.
The main limitation of this study is the lack of a double-
blind condition, as a placebo group was not included. How-
ever, physicians who performed patient evaluations were
blinded to the assigned group, and thus, the objective evalu-
ations are reliable.
As the percentage of patients expected to experience pain or
functional limitation after TKA is significantly higher than after
total hip arthroplasty, the advantages deriving from early con-
trol of joint inflammation can certainly justify the use of I-ONE
therapy in the first two months postoperatively and should be
considered an effective completion of the surgical procedure.
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